MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, BDX, and IDXX
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), and IDEXX Laboratories (IDXX). These companies are all part of the "medical" sector.
Medtronic vs. Its Competitors
Medtronic (NYSE:MDT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Medtronic presently has a consensus price target of $102.14, suggesting a potential upside of 11.06%. DexCom has a consensus price target of $99.89, suggesting a potential upside of 33.04%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Medtronic.
In the previous week, Medtronic had 38 more articles in the media than DexCom. MarketBeat recorded 73 mentions for Medtronic and 35 mentions for DexCom. DexCom's average media sentiment score of 1.25 beat Medtronic's score of 1.12 indicating that DexCom is being referred to more favorably in the news media.
Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
Medtronic has a net margin of 13.63% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Medtronic's return on equity.
82.1% of Medtronic shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.2% of Medtronic shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
DexCom beats Medtronic on 12 of the 17 factors compared between the two stocks.
Get Medtronic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
Related Companies and Tools
This page (NYSE:MDT) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access